IPP Bureau
Carbogen Amcis appoints Stephan Fritschi as CEO
By IPP Bureau - February 04, 2025
Pascal Villemagne has announced his intent to step down at the end of March 2025, to take on a new challenge in his professional career.
Akums combines two potent diabetes medicines for enhanced treatment efficacy
By IPP Bureau - February 04, 2025
Akums Drugs & Pharmaceuticals has launched Dapagliflozin + Pioglitazone tablets, a dual-action therapy for diabetes management
Gland Pharma reports Q3 FY25 revenue at Rs. 1,384 Cr
By IPP Bureau - February 04, 2025
Our Q3 FY25 revenue was at Rs. 1,384.1 crore with an EBITDA of Rs. 360 crore resulting in a 26% EBITDA margin
Zydus Wellness records consolidated net sales growth of 12.7% in Q3 FY25
By IPP Bureau - February 04, 2025
EBITDA rose to Rs. 14.8 crore, marking a 16.5% y-o-y increase, while net profit surged to Rs. 6.4 crore
Sigachi Industries to invest US $1 mn in establishing R&D Centre in Hyderabad
By IPP Bureau - February 04, 2025
The company is committed to revolutionizing API development by advancing synthesis and analytical processes that enhance quality and impact lives
Lupin announces closure of USFDA inspection at its Somerset facility with zero 483 observations
By IPP Bureau - February 03, 2025
The inspection was carried out from January 28 to February 1, 2025
CuraTeQ Biologics receives positive opinion for biosimilar Dyrupeg from EMA
By IPP Bureau - February 03, 2025
Dyrupeg will be available as 6 mg solution for injection in prefilled syringe and is intended for the reduction in the duration of neutropenia
Jubilant Pharmova Q3 FY25 revenue up 9%
By IPP Bureau - February 03, 2025
EBITDA grew by 11% on a YoY basis to Rs. 296 crore due to improved performance in CDMO Sterile Injectables, CRDMO and Generics
Wockhardt’s Zaynich achieves highest-ever efficacy meeting superiority in a global, pivotal, registration- enabling Phase III study
By IPP Bureau - February 03, 2025
Such combined efficacy (achieving clinical cure and microbiologic cure) of Zaynich is highest ever among all the FDA-approved novel antibiotics developed in the last more than 10 years
Nectar Lifesciences posts Q3 FY25 PAT at Rs. 7.84 Cr
By IPP Bureau - February 03, 2025
Revenue from Operations for Q3 FY25 was Rs. 454.33 crore,
M. S. Dhoni and Emcure's Namita Thapar unite to champion women's health awareness
By IPP Bureau - February 02, 2025
Arth by Emcure is a specialized range of supplements designed to address the unique health and wellness needs of women, enabling them to lead healthier and happier lives across all stages
Allergan Aesthetics launches new AA signature program at IMCAS 2025 to redefine patient-centric, multimodal treatment plans
By IPP Bureau - February 01, 2025
AA Signature provides an innovative approach to treatment planning that focuses on patient outcomes
BMS receives positive CHMP opinion for Opdivo plus Yervoy as a first-line treatment option for advanced hepatocellular carcinoma
By IPP Bureau - February 01, 2025
Recommendation based on results of Phase 3 CheckMate -9DW clinical trial demonstrating statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in this patient population
MicrobioTx introduces innovative probiotic range for personalized wellness
By IPP Bureau - February 01, 2025
These solutions combine scientifically or clinically validated, regulatory-approved probiotic strains with precise dosing
Roche receives FDA approval for the first companion diagnostic to identify patients ultralow metastatic breast cancer
By IPP Bureau - February 01, 2025
The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, is now also approved to aid in the assessment of HER2-ultralow status for metastatic breast cancer patients.
